Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TPH1 | P17752 | 2/20 | 0.40 |
| ▸ | FCER2 | P06734 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295546 | 0.86 | TAS1R3 (0.38) | TAS1R3TAS1R1ACACBFCER2CCR1 | |
| SCHEMBL21690018 | 0.84 | PKM (0.55) | ACACBPKMTPH1FCER2PTPN1 | |
| SCHEMBL31711179 | 0.84 | PKM (0.55) | ACACBPKMTPH1FCER2PTPN1 | |
| SCHEMBL5783367 | 0.84 | PKM (0.55) | ACACBPKMTPH1FCER2PTPN1 | |
| SCHEMBL2297609 | 0.84 | PKM (0.55) | ACACBPKMTPH1FCER2PTPN1 | |
| SCHEMBL5520908 | 0.83 | PTPN1 (0.46) | TAS1R3TAS1R1FCER2PTPN1 | |
| SCHEMBL3882884 | 0.80 | CTSS (0.41) | TAS1R3TAS1R1KDM4EHSD17B10SMN1; SMN2 | |
| Phenylalanine SCHEMBL2341512 | 0.79 | SLC7A5 (0.59) | PKMSLC7A5PTGS1 | |
| SCHEMBL2300221 | 0.75 | LTA4H (0.49) | PKMSLC7A5PTGS1 | |
| SCHEMBL14978953 | 0.75 | ALOX15 (0.52) | TAS1R3TAS1R1ACACBFCER2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-7119080-B2 | For use as inhibitors of proteasome; for reducing the rate of degradation of proteins in an animal | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060122390-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| US-6617317-B1 | Reducing the rate of degradation of proteins in an animal | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-6066730-A | Boronic ester and acid compounds, synthesis and uses | PROSCRIPT, INC. | 2000-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122390-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | TAS1R3 4301/4885TAS1R1 4268/4885ACACB 1329/4885 |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | TAS1R3 4301/4885TAS1R1 4268/4885ACACB 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.